tiprankstipranks
GENFIT SA Showcases Robust 2024 Financial Health
Company Announcements

GENFIT SA Showcases Robust 2024 Financial Health

Genfit SA (GNFT) has released an update.

Pick the best stocks and maximize your portfolio:

GENFIT SA reported strong first half-year 2024 financial results, with €61.6 million in cash reserves and €59.0 million in revenue, bolstered by a €48.7 million milestone from U.S. sales of its PBC treatment, Iqirvo. The company anticipates additional European momentum with an expected €26.5 million milestone following Iqirvo’s anticipated pricing and reimbursement approval. GENFIT’s advancements in liver disease treatments and diagnostics, alongside positive U.S. market reception, position it optimistically for future developments.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit Advances Liver Disease Programs Amid Promising Developments
TipRanks Auto-Generated NewsdeskGenfit’s Revenue Surge Driven by Key Milestone
TipRanks Auto-Generated NewsdeskGenfit’s Iqirvo Wins EU Approval for Liver Condition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App